Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company specializing in Antibody Drug Conjugates (ADCs), announced that shareholders approved all management proposals with overwhelming majorities at the company's ordinary virtual Annual General Meeting held on June 23, 2026. The approvals ranged between 98.67% and 98.72%, reflecting strong shareholder support for the company's strategic direction.
Key outcomes of the meeting included the formal approval of the actions of the Management Board and Supervisory Board for the 2024/2025 financial year, the appointment of auditors for the 2025/2026 financial year, and the approval of the remuneration report for the Management Board. Additionally, shareholders elected Jack Yefei Ling as a new member of the Supervisory Board and approved an amendment to the Articles of Association to reduce the size of the Supervisory Board from seven to five members. Attendance at the meeting, including postal votes, represented 80.55% of the current capital stock.
Heidelberg Pharma is pioneering the use of Amanitin, a toxin derived from the green death cap mushroom, in its ADC technology platform known as ATAC. The lead candidate HDP-101 (INN: pamlectabart tismanitin) targets BCMA for multiple myeloma and has received Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration. Other candidates include HDP-102 for Non-Hodgkin Lymphoma, HDP-103 for metastatic castration-resistant prostate cancer, and HDP-104 for gastrointestinal tumors such as colorectal cancer, which have completed preclinical development and are available for partnering.
The election of Jack Yefei Ling to the Supervisory Board signals potential strategic shifts or enhanced oversight as the company advances its pipeline. The reduction in board size may streamline decision-making processes. For investors and industry observers, the strong shareholder approval indicates confidence in Heidelberg Pharma's management and its innovative ATAC technology. The company's focus on ADCs using a novel toxin from a death cap mushroom represents a differentiated approach in oncology, with implications for the broader biotech sector as targeted cancer therapies continue to evolve.
Detailed voting results and further information about the Annual General Meeting are available at Heidelberg Pharma's AGM page. The company is listed on the Frankfurt Stock Exchange and provides more information at www.heidelberg-pharma.com.
